Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Queen's University (Kingston, Ontario)
$120,000.00
Investigating clonal hematopoiesis as a driver of respiratory morbidity, infection risk, and vaccine-related immune dysfunction
FY 2025-26
Summary
Clonal hematopoiesis (CH) is a condition that emerges as we age, affecting more than one in ten adults over 65. In CH, a significant portion of an individual's blood cells are made from a single, abnormal stem cell, increasing the risk of cancer, chronic disease, overall infection, and early death. While research has shown that CH disrupts immunity, we still do not fully understand its impact on the lungs, infections, and vaccine responses. These gaps are critical because lung infections and disease are leading global causes of hospitalization and death in older adults. Vaccines are key preventative tools, but they rely on strong immune responses, which may be compromised. Thus, our project will study whether CH is linked to a greater risk of lung disease and infections, and how it may shape responses to vaccines or immunotherapies.
First, we will analyze large-scale health databases to test whether people with CH are more likely to have asthma, COPD, influenza, or COVID-19; and whether they face worse outcomes like hospitalization or intensive care. We will also explore whether CH contributes to frailty, a major risk factor for poor recovery after infection in older adults. Second, we will use blood samples from influenza and COVID-19 vaccine trials to measure whether people with CH mount weaker immune responses, and whether stronger doses or alternative strategies could improve protection. Finally, we will extend this work to cancer immunotherapy by studying whether CH alters responses to BCG, a vaccine-based treatment for bladder cancer.
Together, this study will deliver the first comprehensive understanding of how CH shapes lung health, infection risk and vaccine response. The results will enable identification of high-risk older adults, inform optimized vaccine strategies, and guide new therapies targeting CH. Ultimately, this work will help ageing populations live longer, healthier lives with fewer hospital visits, while easing strain on the healthcare system.
Department
Program
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Location
Ontario, Canada
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
560310
Name
Patel Zil
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Investigating clonal hematopoiesis as a driver of respiratory morbidity, infection risk, and vaccine-related immune dysfunction
Programtype2
Studentship Programs
Orgnameinp2
Queen's University (Kingston, Ontario)
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Cancer Genetics; Clonal Hematopoiesis; Computational Biology And Bioinformatics; Immune Dysfunction; Inflammageing; Longitudinal Cohort Study; Population Health; Proteomics And Immunophenotyping; Respiratory Disease And Infection; Vaccine Responsiveness
Abstract
Clonal hematopoiesis (CH) is a condition that emerges as we age, affecting more than one in ten adults over 65. In CH, a significant portion of an individual's blood cells are made from a single, abnormal stem cell, increasing the risk of cancer, chronic disease, overall infection, and early death. While research has shown that CH disrupts immunity, we still do not fully understand its impact on the lungs, infections, and vaccine responses. These gaps are critical because lung infections and disease are leading global causes of hospitalization and death in older adults. Vaccines are key preventative tools, but they rely on strong immune responses, which may be compromised. Thus, our project will study whether CH is linked to a greater risk of lung disease and infections, and how it may shape responses to vaccines or immunotherapies.
First, we will analyze large-scale health databases to test whether people with CH are more likely to have asthma, COPD, influenza, or COVID-19; and whether they face worse outcomes like hospitalization or intensive care. We will also explore whether CH contributes to frailty, a major risk factor for poor recovery after infection in older adults. Second, we will use blood samples from influenza and COVID-19 vaccine trials to measure whether people with CH mount weaker immune responses, and whether stronger doses or alternative strategies could improve protection. Finally, we will extend this work to cancer immunotherapy by studying whether CH alters responses to BCG, a vaccine-based treatment for bladder cancer.
Together, this study will deliver the first comprehensive understanding of how CH shapes lung health, infection risk and vaccine response. The results will enable identification of high-risk older adults, inform optimized vaccine strategies, and guide new therapies targeting CH. Ultimately, this work will help ageing populations live longer, healthier lives with fewer hospital visits, while easing strain on the healthcare system.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Patel, Zil
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~